PLAIAR-Trial: Platelets in Inflammation and Resolution

NCT ID: NCT05098106

Last Updated: 2021-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

72 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-01

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Detection and determination of platelets in bronchoalveolar lavage fluid and blood in ARDS and non-ARDS-patients. Correlation with phenotype and inflammation parameters in blood and outcome parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ARDS Platelet Abnormality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pneumonia patients with ARDS

Patients in the perioperative/intensive care setting with pneumonia-induced ARDS requiring bronchoscopy.

Bronchoscopy, blood sampling; testing.

Intervention Type DIAGNOSTIC_TEST

BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.

Ventilated patients without ARDS

Patients without ARDS on mechanical ventilation.

Bronchoscopy, blood sampling; testing.

Intervention Type DIAGNOSTIC_TEST

BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bronchoscopy, blood sampling; testing.

BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Routine bronchoscopy
* Patient in perioperative setting
* Age \>=18 years
* Consent

Exclusion Criteria

* Active or recent (in past 7 days) bleeding in upper airways
* Recent traumatic injury of the lung associated with (micro-)hemorrhage
* Blood aspiration
* Pregnancy
* Age\<18 years
* Acute kidney injury / Chronic kidney failure / Dialysis
* Transplantation
* HIV
* Hematologic diseases
* Immunosuppression
* Anti-Platelet-Therapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Study Chair and Principal Investigator: Univ.-Prof. Dr. Alexander Zarbock

UNKNOWN

Sponsor Role collaborator

Principal Investigator: Dr. Andreas Margraf

UNKNOWN

Sponsor Role collaborator

University Hospital Muenster

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alexander Zarbock, Univ.-Prof. Dr.

Role: STUDY_CHAIR

University Hospital Muenster

Andreas Margraf, Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Muenster

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Muenster

Münster, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carola Wempe, Dr

Role: CONTACT

Phone: +4925147255

Email: [email protected]

Andreas Margraf, Dr

Role: CONTACT

Phone: +492518346843

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Carola Wempe, Dr.

Role: primary

Andreas Margraf, Dr.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12-Anit-20

Identifier Type: -

Identifier Source: org_study_id